


Supplementary Fig. S7



Amplification of BCL2A1 is associated with lower survival ability in ovarian cancer patients. The BCL2A1 gene copy number data together with the patient survival data of ovarian serous cancer (TCGA, 2011) were downloaded from cBioPortal (<http://www.cbioportal.org/>). Kaplan-Meier survival analysis was performed based on the BCL2A1 amplification showed that the amplification of BCL2A1 was associated with lower survival ability, with a hazard ratio of 1.672, and a log-rank test p-value of 0.1034.